MiniMed Group MMED
$16.01 −$0.25 (-1.54%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.21 +1.25%
Open$16.08
Prev close$16.26
Day range$15.92 – $16.79
Volume4.58M
Market cap$4.50B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q1, ended Jul 2026
Revenue$843.00M+16.6% YoY
Operating profit$2.00M-33.3% YoY
Net profit$0.00+100.0% YoY
Diluted EPS$0.00+100.0% YoY
Free cash flow-$90.00M+53.6% YoY
Operating cash flow-$49.00M
Revenue, last 7 quarters
Net profit, last 7 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin53.9%
Operating margin-5.0%
Net margin-9.7%
Return on equity-8.7%
Return on assets-6.7%
Return on invested capital-8.7%
Current ratio1.81
Liabilities / assets23.3%
Cash & investments$207.00M
Net cash (debt)$207.00M
Where the revenue comes from
Quarter 2027/Q1
By business line
Balance sheet
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| Stockholders' Equity | $3.62B | $3.61B | $3.61B | $3.46B | $3.74B |
| Other Non-Current Assets | $152.00M | $147.00M | $147.00M | $146.00M | $150.00M |
| -Other Intangible Assets | $99.00M | $106.00M | $106.00M | $112.00M | $119.00M |
| -Goodwill | $2.26B | $2.26B | $2.26B | $2.26B | $2.26B |
| Goodwill and Other Intangible Assets | $2.35B | $2.36B | $2.36B | $2.37B | $2.38B |
| Non Current Accounts Receivables | $58.00M | $61.00M | $61.00M | $19.00M | $64.00M |
| Net PPE | $736.00M | $711.00M | $711.00M | $701.00M | $755.00M |
| Total Non-Current Assets | $3.30B | $3.28B | $3.28B | $3.23B | $3.34B |
| Other Current Assets | $72.00M | $54.00M | $54.00M | $38.00M | $13.00M |
| Inventory | $356.00M | $341.00M | $341.00M | $407.00M | $362.00M |
| -Due from Related Parties Current | $602.00M | $455.00M | $455.00M | – | – |
| -Accounts Receivable | $180.00M | $200.00M | $200.00M | $653.00M | $166.00M |
| Total Liabilities | $1.10B | $1.02B | $1.02B | $880.00M | $491.00M |
| Total Current Liabilities | $782.00M | $702.00M | $702.00M | $696.00M | $350.00M |
| Total Equity | $3.62B | $3.61B | $3.61B | $3.46B | $3.74B |
| Other Non-Current Liabilities | $316.00M | $317.00M | $317.00M | $184.00M | $141.00M |
| Total Non-Current Liabilities | $316.00M | $317.00M | $317.00M | $184.00M | $141.00M |
| Other Current Liabilities | -$1.00M | $1.00M | $1.00M | -$1.00M | -$1.00M |
| Current Deferred Liabilities | $14.00M | $15.00M | $15.00M | $13.00M | – |
| -Current Capital Lease Obligation | $9.00M | $8.00M | $8.00M | $11.00M | – |
| Current Accrued Expenses | $129.00M | $177.00M | $177.00M | $186.00M | $128.00M |
| -Due to Related Parties Current | $178.00M | – | – | – | – |
| -Total Tax Payable | $76.00M | $38.00M | $38.00M | – | – |
| -Accounts Payable | $251.00M | $163.00M | $163.00M | $303.00M | $129.00M |
| Payables | $505.00M | $201.00M | $201.00M | $303.00M | $129.00M |
| Receivables | $782.00M | $655.00M | $655.00M | $653.00M | $166.00M |
| -Cash and Cash Equivalents | $207.00M | $298.00M | $298.00M | $10.00M | $350.00M |
| Cash and Cash Equivalents & Short-Term Investments | $207.00M | $298.00M | $298.00M | $10.00M | $350.00M |
| Total Current Assets | $1.42B | $1.35B | $1.35B | $1.11B | $891.00M |
| Total Assets | $4.72B | $4.63B | $4.63B | $4.34B | $4.24B |
| Capital Stock | $3.00M | $3.00M | $3.00M | – | $3.00M |
| -Common Stock | $3.00M | $3.00M | $3.00M | – | $3.00M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | – | – |
| Retained Earnings | -$116.00M | -$116.00M | -$116.00M | – | -$5.00M |
| Short-Term Debt and Capital Lease Obligation | $9.00M | $145.00M | $145.00M | $11.00M | – |
| Gains/Losses Not Affecting Retained Earnings | -$14.00M | -$12.00M | -$12.00M | $14.00M | $8.00M |
| Additional Paid-In Capital | $3.75B | $3.74B | $3.74B | – | $3.74B |
| -Accumulated Depreciation | – | -$781.00M | -$781.00M | – | – |
| -Gross PPE | – | $1.49B | $1.49B | – | – |
| Minority Interests | – | $0.00 | $0.00 | – | – |
| -Current Debt | – | $137.00M | $137.00M | – | – |
| Other Equity Interests | – | – | – | $3.45B | – |
Cash flow
| Line item | 2027 Q1 | 2026 Q4 | 2026 ANNUAL | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| -Change in Payables and Accrued Expense | $78.00M | $204.00M | $178.00M | $126.00M | $19.00M |
| -Change in Inventory | -$15.00M | $64.00M | -$29.00M | -$43.00M | -$20.00M |
| -Change in Receivables | -$148.00M | -$444.00M | -$538.00M | -$74.00M | -$15.00M |
| Change in Working Capital | -$110.00M | $12.00M | -$166.00M | $22.00M | -$12.00M |
| Other Non-Cash Items | $2.00M | $3.00M | $19.00M | $4.00M | $2.00M |
| Deferred Tax | $2.00M | -$55.00M | -$54.00M | – | – |
| Depreciation & Depletion & Amortization | $41.00M | $39.00M | $156.00M | $39.00M | $39.00M |
| Net Income from Continuing Operations | $0.00 | -$185.00M | -$317.00M | -$111.00M | -$5.00M |
| Net cash flow from continuing operations | -$50.00M | -$171.00M | -$197.00M | $67.00M | $47.00M |
| Operating Cash Flow | -$49.00M | -$170.00M | -$197.00M | $66.00M | $48.00M |
| -Change In Other Working Capital | -$25.00M | $31.00M | $66.00M | $13.00M | $4.00M |
| Net cash flow from investing | -$41.00M | -$56.00M | -$233.00M | -$53.00M | -$61.00M |
| Free Cash Flow | -$90.00M | -$226.00M | -$420.00M | $13.00M | -$13.00M |
| Effect of Exchange Rate Changes | -$1.00M | – | $1.00M | – | – |
| Beginning Cash Balance | $298.00M | $10.00M | $11.00M | $8.00M | $9.00M |
| Net Change in Cash | -$90.00M | $287.00M | $286.00M | $2.00M | -$1.00M |
| Ending Cash Balance | $207.00M | $298.00M | $298.00M | $10.00M | $8.00M |
| Net Cash Flow from Continuing Financing Activities | $0.00 | $512.00M | $716.00M | -$11.00M | $13.00M |
| Financing Cash Flow | $0.00 | $512.00M | $716.00M | -$11.00M | $13.00M |
| Net PPE Purchase and Sale | -$41.00M | -$56.00M | -$223.00M | -$53.00M | -$61.00M |
| Net Cash Flow from Continuing Investing Activities | -$41.00M | -$56.00M | -$233.00M | -$53.00M | -$61.00M |
| Net Other Investing Changes | – | $0.00 | -$10.00M | $0.00 | $0.00 |
| Net Other Financing Charges | – | -$26.00M | $178.00M | -$11.00M | $13.00M |
| Gain/Loss from Continuing Operations | – | $1.00M | $7.00M | $2.00M | $2.00M |
| -Change in Other Current Liabilities | – | – | $157.00M | – | – |
| Net Common Stock Issuance | – | – | $538.00M | – | – |
| Net Investment Purchase and Sale | – | – | $0.00 | – | – |
Income statement
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 | 2026 Q2 |
|---|---|---|---|---|---|
| Basic EPS | $0.00 | -$1.30 | -$0.66 | -$0.42 | -$0.10 |
| Net Income to Parent Company | $0.00 | -$333.00M | -$185.00M | -$119.00M | -$27.00M |
| Net Income to Common Stockholders | $0.00 | -$333.00M | -$185.00M | -$119.00M | -$27.00M |
| Diluted EPS | $0.00 | -$1.30 | -$0.66 | -$0.42 | -$0.10 |
| Minority Interests | $0.00 | $16.00M | $0.00 | $8.00M | -$3.00M |
| Profit from Continuing Operations | $0.00 | -$317.00M | -$185.00M | -$111.00M | -$31.00M |
| Net Profit | $0.00 | -$317.00M | -$185.00M | -$111.00M | -$30.00M |
| Tax | $4.00M | $128.00M | $93.00M | $12.00M | $19.00M |
| Pretax Profit | $4.00M | -$189.00M | -$92.00M | -$99.00M | -$12.00M |
| -Less:Other Special Charges | -$2.00M | $18.00M | $7.00M | -$6.00M | $0.00 |
| Operating Expense | $463.00M | $1.84B | $567.00M | $455.00M | $438.00M |
| Cost of Revenue | $378.00M | $1.42B | $357.00M | $428.00M | $324.00M |
| Total Operating Revenue | $843.00M | $3.10B | $837.00M | $790.00M | $752.00M |
| Total Revenue as Reported | $843.00M | $3.10B | $837.00M | $790.00M | $752.00M |
| Special Income (Charges) | $2.00M | -$31.00M | -$6.00M | -$7.00M | $0.00 |
| Gross Profit | $465.00M | $1.68B | $480.00M | $362.00M | $428.00M |
| Selling and Admin Expenses | $312.00M | $1.18B | $299.00M | $309.00M | $318.00M |
| Research & Development | $115.00M | $448.00M | $99.00M | $114.00M | $111.00M |
| Other Income (Expense) | $2.00M | -$30.00M | -$5.00M | -$7.00M | -$1.00M |
| Operating Profit | $2.00M | -$159.00M | -$87.00M | -$93.00M | -$10.00M |
| Other Operating Expenses | $36.00M | $208.00M | $169.00M | $32.00M | $9.00M |
| -Selling & Marketing Expense | – | $1.18B | $299.00M | $309.00M | – |
| Other Non-Operating Income (Expenses) | – | $1.00M | – | – | – |
| -Less:Restructuring and Mergern & Acquisition | – | $13.00M | -$1.00M | $13.00M | – |
No comments yet — be the first to weigh in on MMED.
Sign in to join the discussion.